Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 1/20 | 0.56 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.56 |
| ▸ | HCRTR2 | O43614 | 18/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 16/20 | 0.45 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24660474 | 0.92 | HCRTR2 (0.50) | HCRTR2HCRTR1 | |
| SCHEMBL27227366 | 0.86 | ROCK1 (0.46) | LOXLOXL2HCRTR2HCRTR1 | |
| SCHEMBL4937719 | 0.85 | HDAC6 (0.47) | HCRTR2HCRTR1MAP3K12 | |
| SCHEMBL18069308 | 0.84 | ROCK1 (0.50) | LOXLOXL2HCRTR2HCRTR1 | |
| SCHEMBL15649616 | 0.84 | ROCK1 (0.50) | LOXLOXL2HCRTR2HCRTR1 | |
| SCHEMBL27303190 | 0.84 | HCRTR2 (0.43) | HCRTR2HCRTR1 | |
| Hydrochloric Acid SCHEMBL18049105 | 0.83 | ROCK1 (0.49) | HCRTR2HCRTR1 | |
| Hydrochloric Acid SCHEMBL18049143 | 0.83 | ROCK1 (0.49) | HCRTR2HCRTR1 | |
| SCHEMBL450089 | 0.82 | HRH3 (0.57) | HCRTR2HCRTR1 | |
| SCHEMBL911496 | 0.80 | SLC6A2 (0.54) | HCRTR2HCRTR1MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | LOX 3999/4885LOXL2 3365/4885HCRTR2 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.